Douglas Bishop
Family Medicine · Dover, NJNPI 1437354883
Payments from drug & device makers
Across 83 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$171
- Gilead$135
- Braeburn Inc.$127
- Medtronic$108
- GSK$106
- Alkermes, Inc.$93
- plus $528 from 17 others
What the payments were for
- Food & beverage$1,267100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 12 | $171 |
| Gilead | 10 | $135 |
| Braeburn Inc. | 8 | $127 |
| Medtronic | 5 | $108 |
| GSK | 7 | $106 |
| Alkermes, Inc. | 5 | $93 |
| Indivior Inc. | 5 | $75 |
| AbbVie(2 entities) | 5 | $67 |
| Pfizer | 4 | $65 |
| Johnson & Johnson | 4 | $64 |
| Sanofi-aventis U.S. LLC | 4 | $55 |
| Amgen | 2 | $28 |
| Novo Nordisk | 2 | $25 |
| Lilly USA, LLC | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Bayer | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
| Smith+Nephew | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$1,267 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 35 | $51,804 |
| EliquisApixaban | 27 | $38,550 |
| OzempicSemaglutide | 39 | $37,645 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $23,321 |
| JanuviaSitagliptin Phosphate | 14 | $16,316 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 40 | $9,107 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,997 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $5,045 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 116 | $2,788 |
| Lidocaine | 22 | $2,061 |
| Omeprazole | 100 | $1,960 |
| Atorvastatin Calcium | 288 | $1,899 |
| Zolpidem Tartrate ErZolpidem Tartrate | 13 | $1,668 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 25 | $1,241 |
| Gabapentin | 90 | $1,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia | $171 | $39,63728 claims |
| PfizerEliquis | $65 | $38,55027 claims |
| Novo NordiskOzempic | $25 | $37,64539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Dover
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.